FDAnews
www.fdanews.com/articles/97417-lpath-demonstrates-strong-safety-profile-sphingomab

Lpath Demonstrates Strong Safety Profile Sphingomab

August 20, 2007

Lpath reported the completion of  a standard panel of safety tests with the humanized version of Sphingomab, a potential treatment for cancer and other diseases, and the findings indicate no safety concern for systemic dosing of the antibody to humans.

The safety tests included cardiovascular studies in cynomolgus monkeys, as well as tests to evaluate the potential of the antibody to elicit the release of cytokines or an antibody-dependent cell-mediated cytotoxicity reaction, Lpath said.

This study featured intravenous administration of humanized Sphingomab at doses as great as 100 mg/kg every three days for 28 days (10 total doses), the company added.

According to the company, no animal deaths occurred during the study. There were also no significant clinical changes observed during, or following dose administration of 0, 3, 10, 30 or 100 mg/kg.